
|Videos|March 26, 2018
Would Outcomes-Based Contracting be Beneficial for Orphan Drugs?
Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the potential merits of outcomes-based contracting for drugs that treat rare diseases.
Advertisement
Outcomes-based contracting can be very beneficial for specialty pharmacies, and we certainly have a role to play. We are at the center of the patients care once they leave the physician’s office, particularly with the new oral and self-administered medications.
That being said, there’s only certain factors that as a pharmacy we can control related to those outcomes. So, I think where the value comes into outcomes-based contracting is really helping us as pharmacies show what we can control and how we can impact patient outcomes.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5


















































































































